

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **CONNECTED TRANSACTION PROVISION OF FINANCIAL ASSISTANCE**

#### **EXTENDED SHAREHOLDER LOAN**

On 27 September 2019, Lee's International, a wholly owned subsidiary of the Company, and PPI entered into the Supplemental Agreement, pursuant to which Lee's International and PPI agree that the Shareholder Loan in the principal amount of HK\$3,000,000 shall be renewed for an extended term from 27 September 2019 to 26 September 2020.

#### **LISTING RULES IMPLICATIONS**

GL Partners is a substantial shareholder of the Company and therefore, a connected person of the Company under the Listing Rules as at the date of this announcement.

At the same time, Lee's International and GL Partners are both shareholders of PPI, while GL Partners, being a connected person of the Company, is entitled to exercise or control the exercise of 10% or more of the voting power at any general meeting of PPI. Therefore PPI is a commonly held entity falling within the meaning of Rule 14A.27 of the Listing Rules. Therefore, the Extended Shareholder Loan made by Lee's International to PPI under the Supplemental Agreement constitutes a connected transaction of the Company pursuant to Rule 14A.26 of the Listing Rules.

The highest applicable percentage ratio under the Listing Rules for the Extended Shareholder Loan and Previous Financial Assistance made by the Company (by itself or through Lee's International), on a standalone and on an aggregated basis, does not exceed 5%. Therefore, in accordance with Rule 14A.76(2) of the Listing Rules, the Extended Shareholder Loan is only subject to the reporting and announcement requirements and is exempt from the circular (including independent financial advice) and shareholders' approval requirements of the Listing Rules.

\* For identification purpose only

## **EXTENDED SHAREHOLDER LOAN**

On 27 September 2019, Lee's International, a wholly owned subsidiary of the Company, and PPI entered into the Supplemental Agreement, pursuant to which Lee's International and PPI agree that the Shareholder Loan in the principal sum of HK\$3,000,000 shall be renewed for an extended term from 27 September 2019 to 26 September 2020.

### **The Supplemental Agreement**

#### **Date**

27 September 2019

#### **Parties**

- (1) Lee's International, a wholly owned subsidiary of the Company, as lender; and
- (2) PPI, as borrower.

PPI is a commonly held entity falling within the meaning of Rule 14A.27 of the Listing Rules.

#### **Subject matter**

Pursuant to the Supplemental Agreement, Lee's International and PPI agree to renew the Shareholder Loan in the principal sum of HK\$3,000,000 for an extended term from 27 September 2019 to 26 September 2020.

#### **Principal amount of the Extended Shareholder Loan**

HK\$3,000,000

#### **Interest rate**

Interest on the Extended Shareholder Loan shall accrue at 4% per annum, which is determined with reference to the prevailing interest rate in the market.

Interest on the Extended Shareholder Loan shall accrue and be calculated for the period commencing from 27 September 2019 up to (but excluding) the Repayment Date.

#### **Extended term**

Subject to early repayment as provided under the Supplemental Agreement, the term of the Extended Shareholder Loan shall be commencing from 27 September 2019 and expiring on 26 September 2020.

## **Repayment schedule**

PPI shall repay the Extended Shareholder Loan together with the interest accrued on the Repayment Date.

PPI shall have the right to make early repayment of the Extended Shareholder Loan, together with the interest accrued at any time during the abovementioned extended term for the Extended Shareholder Loan by giving the Written Notice to Lee's International. PPI shall specify in the Written Notice the date when the early repayment of the Extended Shareholder Loan shall be made.

## **REASONS FOR AND BENEFITS OF THE EXTENDED SHAREHOLDER LOAN**

PPI is in the course of expanding its business operation in producing, developing and in promoting the sale of medical devices. To ensure such steady growth will be backed by ample financial resources, PPI needs the funding as obtained under the Extended Shareholder Loan. Therefore, after arm's length negotiation between PPI and Lee's International (being a shareholder of PPI), Lee's International agrees to advance the Extended Shareholder Loan for an extended term from 27 September 2019 to 26 September 2020 in order to support the sustained development of PPI and to allow PPI a higher degree of flexibility in its cash flow. The Extended Shareholder Loan would be utilised for PPI's general working capital and the provision of financial assistance will generate additional profit attributable to the Shareholders.

The Directors (including the independent non-executive Directors) considered that the terms of the Supplemental Agreement and the transactions contemplated thereunder, which have been entered into after arm's length negotiation between Lee's International and PPI, are not in the ordinary and usual course of business of the Group but are on normal commercial terms and the terms therein are fair and reasonable and in the interest of the Company and the Shareholders as a whole.

Dr. Li Xiaoyi, an executive Director and a substantial shareholder of the Company, is directly and indirectly (through Swift Power) interested in the issued share capital of PPI, and in view of such interests, he is considered to have an interest in the transaction contemplated under the Supplemental Agreement, and is required to abstain, or has abstained, from voting on the relevant Board resolutions to approve the Supplemental Agreement. Save for the above, no Director has a material interest in the transactions contemplated under the Supplemental Agreement, and none of them is required to abstain or has abstained from, voting on the relevant Board resolutions to approve the Supplemental Agreement.

## **INFORMATION OF PPI**

PPI was incorporated in the British Virgin Islands on 6 August 2009, and is currently carrying on the business of, inter alia, producing, developing and sale of Zingo and the platform together with the accompanying powder intra-dermal injection system, and other medical devices such as the developing of continuous glucose monitoring system.

## **GENERAL INFORMATION OF THE GROUP**

The Group is a research-driven and market-oriented biopharmaceutical company focused on the PRC market. Through its operating subsidiary in the PRC, the Group develops, manufactures and markets proprietary pharmaceutical products in the PRC. It has established a sale and distribution network for pharmaceuticals covering most provinces and cities in the PRC, marketing both self-developed products and licensed products from abroad. The principal business activity of Lee’s International is investment holding.

## **LISTING RULES IMPLICATIONS**

GL Partners is a substantial shareholder of the Company and therefore, a connected person of the Company under the Listing Rules as at the date of this announcement.

At the same time, Lee’s International and GL Partners are both shareholders of PPI, while GL Partners, being a connected person of the Company, is entitled to exercise or control the exercise of 10% or more of the voting power at any general meeting of PPI. Therefore PPI is a commonly held entity falling within the meaning of Rule 14A.27 of the Listing Rules. Therefore, the Extended Shareholder Loan made by Lee’s International to PPI under the Supplemental Agreement, constitutes a connected transaction of the Company pursuant to Rule 14A.26 of the Listing Rules.

The highest applicable percentage ratio under the Listing Rules for the Extended Shareholder Loan and Previous Financial Assistance made by the Company (by itself or through Lee’s International), on a standalone and on an aggregated basis, does not exceed 5%. Therefore, in accordance with Rule 14A.76(2) of the Listing Rules, the Extended Shareholder Loan is only subject to the reporting and announcement requirements and is exempt from the circular (including independent financial advice) and shareholders’ approval requirements of the Listing Rules.

## **DEFINITIONS**

In this announcement, the following expressions have the following meanings unless the context requires otherwise:

|                         |  |
|-------------------------|--|
| “Board”                 | board of Directors   |
| “Company”               | Lee’s Pharmaceutical Holdings Limited, a company incorporated in the Cayman Islands with limited liability with its issued shares listed on the Main Board of the Stock Exchange |
| “connected person”      | has the meaning ascribed to it under the Listing Rules   |
| “connected transaction” | has the meaning ascribed to it under the Listing Rules   |

|                             |  |
|-----------------------------|--|
| “Director(s)”               | director(s) of the Company   |
| “Extended Shareholder Loan” | the shareholder loan in the principal amount of HK\$3,000,000 made by Lee’s International to PPI under the Supplemental Agreement  |
| “GL Partners”               | GL Partners Capital Management Limited   |
| “Group”                     | the Company and its subsidiaries   |
| “Guarantee”                 | the guarantee (with the guaranteed amount of HK\$48,000,000) given by the Company in favour of Nanyang Commercial Bank, Limited in respect of the revolving loan facility of up to HK\$8,000,000, the demand loan facility of up to HK\$40,000,000 and overdraft facility of up to HK\$4,000,000 pursuant to the terms of the facility letter issued by Nanyang Commercial Bank, Limited to PPI dated 5 March 2019, which was agreed and accepted by PPI (as borrower) and the Company (as guarantor) on 14 March 2019, provided that the total outstanding balance of the overdraft facility and revolving loan facility shall not at any time exceed HK\$8,000,000 |
| “HK\$”                      | Hong Kong dollars, the lawful currency of Hong Kong  |
| “Hong Kong”                 | Hong Kong Special Administrative Region of the PRC   |
| “Lee’s International”       | Lee’s Pharmaceutical International Limited, a company with limited liability and incorporated under the laws of the British Virgin Islands, and a wholly owned subsidiary of the Company   |
| “Listing Rules”             | Rules Governing the Listing of Securities on the Stock Exchange  |
| “PPI”                       | Powder Pharmaceuticals Incorporated, a company with limited liability and incorporated under the laws of the British Virgin Islands  |
| “PRC”                       | People’s Republic of China, and for the purpose of this announcement shall not include Hong Kong, Macau Special Administrative Region of the PRC and Taiwan  |

|                                 |  |
|---------------------------------|--|
| “Previous Financial Assistance” | the provision of the Previous Shareholder Loan by Lee’s International to PPI and the provision of the Guarantee by the Company   |
| “Previous Shareholder Loan”     | <p>the existing shareholder loans provided by Lee’s International to PPI which comprises of:</p> <ul style="list-style-type: none"> <li>(a) the shareholder loan in the principal amount of HK\$4,000,000 made by Lee’s International to PPI under the shareholder loan agreement dated 29 November 2018 entered into between Lee’s International and PPI;</li> <li>(b) the shareholder loan in the principal amount of HK\$3,000,000 made by Lee’s International to PPI under the shareholder loan agreement dated 28 March 2018 (as supplemented by the supplemental agreement dated 27 March 2019) entered into between Lee’s International and PPI;</li> <li>(c) the shareholder loan in the principal amount of HK\$3,000,000 made by Lee’s International to PPI under the shareholder loan agreement dated 15 June 2018 (as supplemented by the supplemental agreement dated 14 June 2019) entered into between Lee’s International and PPI; and</li> <li>(d) the shareholder loan in the aggregate principal amount of HK\$25,056,000 made by Lee’s International to PPI under the supplemental agreement dated 19 July 2019 entered into between Lee’s International and PPI;</li> </ul> |
| “Repayment Date”                | means 26 September 2020, or if PPI elects to make early repayment, the date as specified in the Written Notice   |
| “Shareholders”                  | holders of the Shares  |
| “Shareholder Loan”              | the shareholder loan in the principal amount of HK\$3,000,000 made by Lee’s International to PPI under the shareholder loan agreement dated 28 September 2018  |

|                                |   |
|--------------------------------|---|
| “Shares”                       | ordinary share(s) of nominal value of HK\$0.05 each in the capital of the Company   |
| “Stock Exchange”               | The Stock Exchange of Hong Kong Limited   |
| “subsidiary” or “subsidiaries” | has the meaning ascribed to it under the Listing Rules  |
| “substantial shareholder”      | has the meaning ascribed to it under the Listing Rules  |
| “Supplemental Agreement”       | The supplemental agreement date 27 September 2019 entered into between Lee’s International and PPI in related to the Extended Shareholder Loan  |
| “Swift Power”                  | Swift Power Investments Limited, a company with limited liability and incorporated under the laws of the British Virgin Islands, and wholly owned by Dr. Li Xiaoyi who is a Director and a substantial shareholder of the Company         |
| “Written Notice”               | the 7-day written notice served by PPI in accordance with the terms of the Supplemental Agreement, which sets out PPI’s intention to make early repayment on the Extended Shareholder Loan together with interest accrued thereon         |
| “Zingo”                        | Lidocaine Hydrochloride Monohydrate, a novel pharmaceutical product for pain management which is a combination drug device indicated for use on intact skin to provide local analgesia prior to veni-puncture and intravenous cannulation |
| “%”                            | per cent  |

By order of the Board  
**Lee’s Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 27 September 2019

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Mr. Simon Miles Ball is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*